A phase 3 trial of bevacizumab in ovarian cancer

Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder, Andreas du Bois, Jalid Sehouli, Rainer Kimmig, Anne Stähle, Fiona Collinson, Sharadah Essapen, Charlie Gourley, Alain Lortholary, Frédéric Selle, Mansoor Raza MirzaArto Leminen, Marie Plante, Dan Stark, Wendi Qian, Mahesh K B Parmar, Amit M Oza, ICON7 Investigators

Research output: Contribution to journalJournal articleResearchpeer-review

1273 Citations (Scopus)
Original languageEnglish
JournalThe New England Journal of Medicine
Volume365
Issue number26
Pages (from-to)2484-96
Number of pages13
ISSN0028-4793
DOIs
Publication statusPublished - 29 Dec 2011
Externally publishedYes

Bibliographical note

Member of the NSGO Group (ICON7 Investigators)

Keywords

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols
  • Bevacizumab
  • Carboplatin
  • Combined Modality Therapy
  • Disease-Free Survival
  • Double-Blind Method
  • Female
  • Humans
  • Middle Aged
  • Neoplasms, Glandular and Epithelial
  • Ovarian Neoplasms
  • Paclitaxel
  • Quality of Life
  • Survival Analysis
  • Clinical Trial, Phase III
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'A phase 3 trial of bevacizumab in ovarian cancer'. Together they form a unique fingerprint.

Cite this